Guardant Health, Inc. $GH Shares Bought by Castleark Management LLC

Castleark Management LLC grew its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 165,043 shares of the company’s stock after purchasing an additional 4,970 shares during the quarter. Castleark Management LLC’s holdings in Guardant Health were worth $16,857,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of GH. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health during the fourth quarter worth about $27,000. Chesapeake Asset Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health during the 4th quarter valued at about $31,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health during the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC raised its holdings in shares of Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Up 0.6%

Shares of Guardant Health stock opened at $131.62 on Friday. The firm has a market cap of $17.45 billion, a P/E ratio of -38.83 and a beta of 1.61. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $134.28. The business has a 50-day moving average price of $103.51 and a 200 day moving average price of $102.14.

Insider Transactions at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 1,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $130.06, for a total transaction of $130,060.00. Following the completion of the sale, the director owned 639 shares of the company’s stock, valued at $83,108.34. This represents a 61.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $128.62, for a total transaction of $257,240.00. Following the sale, the chief financial officer directly owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. This represents a 4.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 452,238 shares of company stock valued at $51,425,612 over the last 90 days. Corporate insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on GH shares. Royal Bank Of Canada started coverage on Guardant Health in a report on Thursday. They set an “outperform” rating and a $185.00 target price on the stock. Raymond James Financial reiterated an “outperform” rating and set a $129.00 target price on shares of Guardant Health in a report on Monday, February 23rd. The Goldman Sachs Group started coverage on Guardant Health in a report on Friday, June 5th. They set a “buy” rating and a $165.00 target price on the stock. Stifel Nicolaus raised their target price on Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 20th. Finally, Barclays raised their target price on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and an average target price of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.